Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease
Authors: Dimitrios Patoulias
Journal: Annals of Internal Medicine (2023)

LettersJuly 2023Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney DiseaseDimitrios Patoulias, MD, MSc, PhDDimitrios Patoulias, MD, MSc, PhDSecond Department of Cardiology, Aristotle University of Thessaloniki, General Hospital Hippokration, Thessaloniki, GreeceSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L23-0069 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR: In their post hoc analysis of the DAPA-CKD (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease) trial, Schechter and colleagues (1) showed that compared with placebo, dapagliflozin resulted in a significant decrease in the risk for a first hospitalization and for all hospitalizations or death. Of note, the presence of type 2 diabetes mellitus at baseline did not affect the observed effect. Moreover, the authors observed that dapagliflozin led to a significant decrease (38%) in the risk for hospitalizations due to underlying benign or malignant neoplasms. According to prespecified eligibility criteria, DAPA-CKD investigators excluded participants ...References1. Schechter M, Jongs N, Chertow GM, et al. Effects of dapagliflozin on hospitalizations in patients with chronic kidney disease. A post hoc analysis of DAPA-CKD. Ann Intern Med. 2023;176:59-66. [PMID: 36469914] doi:10.7326/M22-2115 LinkGoogle Scholar2. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436-1446. [PMID: 32970396] doi:10.1056/NEJMoa2024816 CrossrefMedlineGoogle Scholar3. Kitchlu A, Reid J, Jeyakumar N, et al. Cancer risk and mortality in patients with kidney disease: a population-based cohort study. Am J Kidney Dis. 2022;80:436-448. [PMID: 35405208] doi:10.1053/j.ajkd.2022.02.020 CrossrefMedlineGoogle Scholar4. Benedetti R, Benincasa G, Glass K, et al. Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials. Pharmacol Res. 2022;175:106039. [PMID: 34929299] doi:10.1016/j.phrs.2021.106039 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Dimitrios Patoulias, MD, MSc, PhDAffiliations: Second Department of Cardiology, Aristotle University of Thessaloniki, General Hospital Hippokration, Thessaloniki, GreeceDisclosures: Authors have reported no disclosures of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L23-0069. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEffects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease Meir Schechter , Niels Jongs , Glenn M. Chertow , Ofri Mosenzon , John J.V. McMurray , Ricardo Correa-Rotter , Peter Rossing , Anna Maria Langkilde , C. David Sjöström , Robert D. Toto , David C. Wheeler , and Hiddo J.L. Heerspink Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease Meir Schechter , Glenn M. Chertow , Hiddo J.L. Heerspink Metrics July 2023Volume 176, Issue 7KeywordsCardiology and cardiovascular diseasesClinical trialsEstimated glomerular filtration rateHealth careHeart failureHospitalizationsKidneysRandomized trialsSodium-glucose contransporter-2 inhibitorsType 2 diabetes ePublished: 18 July 2023 Issue Published: July 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...